Aberdeen Group
ABEO icon

Aberdeen Group’s Abeona Therapeutics ABEO Stock Holding History

Aberdeen Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-616,413
Closed -$3.25M – 932
2025
Q4 		$3.25M Buy
+616,413
New +$3.1M 0.01% 739
2025
Q2 		– Sell
-224,356
Closed -$1.07M – 951
2025
Q1 		$1.07M Hold
224,356
– – ﹤0.01% 813
2024
Q4 		$1.25M Sell
224,356
-102,639
-31% -$632K ﹤0.01% 806
2024
Q3 		$2.07M Buy
326,995
+200,647
+159% +$1.05M ﹤0.01% 754
2024
Q2 		$536K Buy
+126,348
New +$645K ﹤0.01% 859

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aberdeen Group's ABEO Position: Q1 2026 in Review

Aberdeen Group sold out of Abeona Therapeutics (ABEO) in Q1 2026, closing a stake of 616,413 shares — an estimated $3.25M sold.

Aberdeen Group first reported a position in ABEO in Q2 2024 and held it in 5 quarters. The position peaked at $3.25M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Aberdeen Group reported no remaining Abeona Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 616,413 Abeona Therapeutics shares in Q1 2026, an estimated $3.25M.
  • Aberdeen Group first reported a position in Abeona Therapeutics in Q2 2024 and held it in 5 quarters.
  • Aberdeen Group's Abeona Therapeutics position peaked at $3.25M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.